ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ATAI icon
101
DELISTED
AtaiBeckley Inc
ATAI
$4.81M 0.22%
913,242
– –
2025 Q3
3 quarters
PRLD icon
102
Prelude Therapeutics
PRLD
$258M
$4.8M 0.22%
900,900
+748,075
+489% +$3.26M
2026 Q1
1 quarter
JATT icon
103
JATT II Acquisition Corp
JATT
$80.9M
$4.75M 0.22%
+417,724
New +$4.44M
2026 Q2
0 quarters
RNTX icon
104
Rein Therapeutics
RNTX
$50.6M
$4.68M 0.21%
+4,500,000
New +$5.45M
2026 Q2
0 quarters
PEPG icon
105
PepGen
PEPG
$161M
$4.66M 0.21%
2,591,085
+983,447
+61% +$1.6M
2025 Q1
5 quarters
CTNM icon
106
Contineum Therapeutics
CTNM
$306M
$4.57M 0.21%
278,961
+2,300
+0.8% +$30.2K
2024 Q3
7 quarters
CATX icon
107
Perspective Therapeutics
CATX
$256M
$4.13M 0.19%
1,210,117
+460,782
+61% +$1.74M
2025 Q4
2 quarters
APGE icon
108
DELISTED
Apogee Therapeutics
APGE
$4.11M 0.19%
+31,000
New +$2.79M
2026 Q2
0 quarters
NAMS icon
109
NewAmsterdam Pharma
NAMS
$2.39B
$4.02M 0.18%
118,623
– –
2025 Q2
4 quarters
CRBP icon
110
Corbus Pharmaceuticals
CRBP
$85.3M
$3.96M 0.18%
421,787
+90,006
+27% +$852K
2025 Q3
3 quarters
BIIB icon
111
Biogen
BIIB
$34.4B
$3.87M 0.18%
17,900
+6,900
+63% +$1.32M
2024 Q3
7 quarters
XNCR icon
112
Xencor
XNCR
$1.74B
$3.74M 0.17%
232,560
+138,895
+148% +$1.73M
2024 Q3
7 quarters
SLN icon
113
Silence Therapeutics
SLN
$558M
$3.72M 0.17%
338,373
+166,216
+97% +$1.17M
2023 Q4
10 quarters
SPRB icon
114
Spruce Biosciences
SPRB
$112M
$3.66M 0.17%
67,717
+9,117
+16% +$510K
2025 Q4
2 quarters
PHVS icon
115
Pharvaris
PHVS
$2.11B
$3.65M 0.17%
105,528
– –
2025 Q2
4 quarters
ENGN icon
116
enGene Therapeutics
ENGN
$105M
$3.64M 0.17%
2,104,986
+1,971,300
+1,475% +$8.04M
2025 Q4
2 quarters
PALI icon
117
Palisade Bio
PALI
$258M
$3.61M 0.17%
1,726,662
-538,183
-24% -$1.06M
2025 Q4
2 quarters
TARA icon
118
Protara Therapeutics
TARA
$147M
$3.59M 0.16%
940,512
– –
2024 Q4
6 quarters
SGMT icon
119
Sagimet Biosciences
SGMT
$535M
$3.38M 0.15%
+437,500
New +$2.98M
2026 Q2
0 quarters
ONC icon
120
BeOne Medicines Ltd
ONC
$39.8B
$3.33M 0.15%
11,701
– –
2026 Q1
1 quarter
IVVD icon
121
Invivyd
IVVD
$179M
$3.32M 0.15%
3,807,427
-15,000
-0.4% -$18.8K
2025 Q3
3 quarters
TENX icon
122
Tenax Therapeutics
TENX
$57.3M
$3.21M 0.15%
220,462
+7,000
+3% +$89.4K
2024 Q3
7 quarters
ZNTL icon
123
Zentalis Pharmaceuticals
ZNTL
$220M
$3.17M 0.14%
652,750
+508,114
+351% +$2.03M
2025 Q2
4 quarters
RLMD icon
124
Relmada Therapeutics
RLMD
$346M
$3.13M 0.14%
451,918
– –
2025 Q4
2 quarters
DCTH icon
125
Delcath Systems
DCTH
$511M
$2.83M 0.13%
224,385
– –
2023 Q4
10 quarters
3 4
5
6 7

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.